Comparative Pharmacology
Head-to-head clinical analysis: FLAVORED COLESTID versus LEROCHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAVORED COLESTID versus LEROCHOL.
FLAVORED COLESTID vs LEROCHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.
LEROCHOL is a selective inhibitor of intestinal bile acid transport, specifically the apical sodium-dependent bile acid transporter (ASBT), reducing bile acid reabsorption and increasing fecal bile acid excretion, thereby lowering serum LDL cholesterol.
5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.
Oral: 10 mg once daily, taken at bedtime without regard to meals.
None Documented
None Documented
Not applicable due to non-absorbable resin; systemic absorption is negligible. Terminal half-life not defined.
Terminal elimination half-life: 12-18 hours. Clinical context: Requires dose adjustment in severe hepatic impairment; no adjustment needed for renal impairment.
Primarily fecal as insoluble complex (90-95%); <5% renal as glucuronide conjugate; minimal biliary elimination.
Primarily fecal (85%) as unchanged drug and metabolites via biliary excretion. Renal excretion accounts for 15%, mostly as glucuronide conjugates.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant